MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/β-catenin in serous ovarian cancers
出版年份 2020 全文链接
标题
MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/β-catenin in serous ovarian cancers
作者
关键词
miR-506-3p, PARP inhibitors, Chemo-resistance, Ovarian cancer
出版物
Translational Oncology
Volume 14, Issue 2, Pages 100987
出版商
Elsevier BV
发表日期
2020-12-22
DOI
10.1016/j.tranon.2020.100987
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
- (2019) Minakshi Mann et al. Oncotarget
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study
- (2017) E. Pujade-Lauraine et al. GYNECOLOGIC ONCOLOGY
- EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
- (2017) H Yamaguchi et al. ONCOGENE
- Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy
- (2017) Chongyuan Zhang et al. MEDICAL SCIENCE MONITOR
- MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2
- (2016) Ping Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The rise of genomic profiling in ovarian cancer
- (2016) Rebecca A. Previs et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Precision targeted therapy of ovarian cancer
- (2016) Justin Sapiezynski et al. JOURNAL OF CONTROLLED RELEASE
- The emerging role of miR-506 in cancer
- (2016) Jian Li et al. Oncotarget
- EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells
- (2016) Horacio Cardenas et al. Oncotarget
- MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells
- (2016) Ziqiang Zhu et al. PLoS One
- The inhibition of EZH2 ameliorates osteoarthritis development through the Wnt/β-catenin pathway
- (2016) Linwei Chen et al. Scientific Reports
- Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells
- (2015) Samir H. Barghout et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
- (2015) Jonathan A Ledermann et al. BRITISH JOURNAL OF CANCER
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
- (2015) Guoyan Liu et al. JNCI-Journal of the National Cancer Institute
- Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
- (2015) Guoyan Liu et al. JNCI-Journal of the National Cancer Institute
- MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer
- (2014) Guoyan Liu et al. JOURNAL OF PATHOLOGY
- MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer
- (2014) Yan Sun et al. JOURNAL OF PATHOLOGY
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer
- (2013) Da Yang et al. CANCER CELL
- Acquisition of epithelial–mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway
- (2013) Hao Wang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The Wnt/β-catenin pathway in ovarian cancer: A review
- (2013) Rebecca C. Arend et al. GYNECOLOGIC ONCOLOGY
- Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling
- (2013) Yongpeng Wei et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- PAF and EZH2 Induce Wnt/β-Catenin Signaling Hyperactivation
- (2013) Hae-Yun Jung et al. MOLECULAR CELL
- Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
- (2013) Marcia Hall et al. OncoTargets and Therapy
- FoxM1 and Wnt/ -Catenin Signaling in Glioma Stem Cells
- (2012) A. Gong et al. CANCER RESEARCH
- Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
- (2012) Z. C. Wang et al. CLINICAL CANCER RESEARCH
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Tankyrases Induces Axin Stabilization and Blocks Wnt Signalling in Breast Cancer Cells
- (2012) Renyue Bao et al. PLoS One
- FoxM1 Promotes β-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis
- (2011) Nu Zhang et al. CANCER CELL
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines
- (2011) Smriti Kumar et al. Journal of Ovarian Research
- MicroRNA: Biogenesis, Function and Role in Cancer
- (2010) Leigh-Ann MacFarlane et al. CURRENT GENOMICS
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Targeting the DNA Damage Response in Cancer
- (2009) Mats Ljungman CHEMICAL REVIEWS
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started